

Exhibit 8

2007

USP 30

THE UNITED STATES PHARMACOPEIA

NF 25

THE NATIONAL FORMULARY

Volume 1

By authority of The United States Pharmacopeial Convention, meeting at Washington, D.C., March 9–13, 2005. Prepared by the Council of Experts and published by the Board of Trustees

Official from May 1, 2007

The designation on the cover of this publication, “USP NF 2007,” is for ease of identification only. The publication contains two separate compendia: *The United States Pharmacopeia*, Thirtieth Revision, and the *National Formulary*, Twenty-Fifth Edition.

THE UNITED STATES PHARMACOPEIAL CONVENTION
12601 Twinbrook Parkway, Rockville, MD 20852

SIX-MONTH IMPLEMENTATION GUIDELINE

Beginning with *USP30–NF25*, the *United States Pharmacopeia–National Formulary* and its *Supplements* will become official **six months** after being released to the public. The *USP–NF*, which is released on November 1 of each year, will become official on May 1 of the following year.

This change was adopted to give users more time to bring their methods and procedures into compliance with new and revised *USP–NF* requirements.

The table below describes the new official dates. The 2006 *USP29–NF24*, and the *Supplements* and *Interim Revision Announcements (IRAs)* to that edition, will be official until May 1, 2007, at which time the *USP30–NF25* becomes official.

Publication	Release Date	Official Date	Official Until
<i>USP30–NF25</i>	Nov. 1, 2006	May 1, 2007	May 1, 2008 (except as superceded by <i>Supplements</i> , <i>IRAs</i> , and <i>Revision Bulletins</i>)
<i>First Supplement</i>	Feb. 1, 2007	Aug. 1, 2007	May 1, 2008 (except as superceded by <i>Second Supplement</i> , <i>IRAs</i> , and <i>Revision Bulletins</i>)
<i>Second Supplement</i>	June 1, 2007	Dec. 1, 2007	May 1, 2008 (except as superceded by <i>IRAs</i> and <i>Revision Bulletins</i>)
<i>USP31–NF26</i>	Nov. 1, 2007	May 1, 2008	May 1, 2009 (except as superceded by <i>Supplements</i> , <i>IRAs</i> , and <i>Revision Bulletins</i>)

IRAs will continue to become official on the first day of the second month of the *Pharmacopeial Forum (PF)* issue in which they are published as final. For instance, *IRAs* published as final in the May-June *PF* (issue 3) will become official on June 1. This table gives the details of the *IRAs* that will apply to *USP29–NF24* and *USP30–NF25*.

<i>IRA</i> *	Release Date	Official Date	Revises
Jan. 1, 2007 <i>IRA</i> , <i>PF</i> 33(1)	Jan. 1, 2007	Feb. 1, 2007	<i>USP29–NF24</i> and its <i>Supplements</i>
Mar. 1, 2007 <i>IRA</i> , <i>PF</i> 33(2)	Mar. 1, 2007	April 1, 2007	<i>USP29–NF24</i> and its <i>Supplements</i>
May 1, 2007 <i>IRA</i> , <i>PF</i> 33(3)	May 1, 2007	June 1, 2007	<i>USP30–NF25</i>
July 1, 2007 <i>IRA</i> , <i>PF</i> 33(4)	July 1, 2007	Aug. 1, 2007	<i>USP30–NF25</i> and <i>First Supplement</i>
Sept. 1, 2007 <i>IRA</i> , <i>PF</i> 33(5)	Sept. 1, 2007	Oct. 1, 2007	<i>USP30–NF25</i> and <i>First Supplement</i>
Nov. 1, 2007 <i>IRA</i> , <i>PF</i> 33(6)	Nov. 1, 2007	Dec. 1, 2007	<i>USP30–NF25</i> and its <i>Supplements</i>
Jan. 1, 2008 <i>IRA</i> , <i>PF</i> 34(1)	Jan. 1, 2008	Feb. 1, 2008	<i>USP30–NF25</i> and its <i>Supplements</i>
Mar. 1, 2008 <i>IRA</i> , <i>PF</i> 34(2)	Mar. 1, 2008	April 1, 2008	<i>USP30–NF25</i> and its <i>Supplements</i>

*NOTE—Beginning January 1, 2007, *USP* will cease identifying *IRAs* numerically (*First*, *Second*, etc.) and instead will designate them by the date on which they are published.

Revision Bulletins published on the *USP* website will continue to become official immediately upon publication, unless the *Revision Bulletin* specifies otherwise.

General Chapters, monographs, or monograph revisions that contain a specific official date shall continue to become official upon such specified date, which supercedes the general official date for the publication.

For more information about the change in official dates, please visit the *USP* website at <http://www.usp.org>.

NOTICE AND WARNING

Concerning U.S. Patent or Trademark Rights

The inclusion in *The United States Pharmacopeia* or in the *National Formulary* of a monograph on any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner.

Concerning Use of USP or NF Text

Attention is called to the fact that *USP* and *NF* text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Secretary of the *USPC* Board of Trustees.

Copyright © 2006 The United States Pharmacopeial Convention
12601 Twinbrook Parkway, Rockville, MD 20852

All rights reserved.

ISSN 0195-7996

ISBN 1-889788-47-3

Printed in the United States by Port City Press, Baltimore




Fig. 1. Disintegration apparatus. (All dimensions are expressed in mm.)

capsules have disintegrated except for fragments from the capsule shell. If 1 or 2 capsules fail to disintegrate completely, repeat the test on 12 additional capsules; not fewer than 16 of the total of 18 capsules tested disintegrate completely.

Soft Gelatin Capsules—Proceed as directed under *Hard Gelatin Capsules*. ♦

⟨711⟩ DISSOLUTION

This general chapter is harmonized with the corresponding texts of the *European Pharmacopoeia* and/or the *Japanese Pharmacopoeia*. These pharmacopoeias have undertaken not to make any unilateral change to this harmonized chapter.

Portions of the present general chapter text that are national USP text, and therefore not part of the harmonized text, are marked with symbols (♦, ♦) to specify this fact.

This test is provided to determine compliance with the dissolution requirements \blacklozenge where stated in the individual monograph, for dosage forms administered orally. In this general chapter, a dosage

unit is defined as 1 tablet or 1 capsule or the amount specified. ♦Of the types of apparatus described herein, use the one specified in the individual monograph. Where the label states that an article is enteric-coated, and where a dissolution or disintegration test that does not specifically state that it is to be applied to delayed-release articles is included in the individual monograph, the procedure and interpretation given for *Delayed-Release Dosage Forms* is applied unless otherwise specified in the individual monograph. For hard or soft gelatin capsules and gelatin-coated tablets that do not conform to the *Dissolution* specification, repeat the test as follows. Where water or a medium with a pH of less than 6.8 is specified as the *Medium* in the individual monograph, the same *Medium* specified may be used with the addition of purified pepsin that results in an activity of 750,000 Units or less per 1000 mL. For media with a pH of 6.8 or greater, pancreatin can be added to produce not more than 1750 USP Units of protease activity per 1000 mL.

USP Reference Standards (11)—*USP Chlorpheniramine Maleate Extended-Release Tablets RS* (Drug Release Calibrator, Single Unit). *USP Prednisone Tablets RS* (Dissolution Calibrator, Disintegrating). *USP Salicylic Acid Tablets RS* (Dissolution Calibrator, Nondisintegrating). ♦

This material may be protected by Copyright law (Title 17 U.S. Code)

APPARATUS

Apparatus 1 (Basket Apparatus)

The assembly consists of the following: a vessel, which may be covered, made of glass or other inert, transparent material¹; a motor; a metallic drive shaft; and a cylindrical basket. The vessel is partially immersed in a suitable water bath of any convenient size or heated by a suitable device such as a heating jacket. The water bath or heating device permits holding the temperature inside the vessel at $37 \pm 0.5^\circ$ during the test and keeping the bath fluid in constant, smooth motion. No part of the assembly, including the environment in which the assembly is placed, contributes significant motion, agitation, or vibration beyond that due to the smoothly rotating stirring element. An apparatus that permits observation of the specimen and stirring element during the test is preferable. The vessel is cylindrical, with a hemispherical bottom and *with one of the following dimensions and capacities: for a nominal capacity of 1 L, the height is 160 mm to 210 mm and its inside diameter is 98 mm to 106 mm; *for a nominal capacity of 2 L, the height is 280 mm to 300 mm and its inside diameter is 98 mm to 106 mm; and for a nominal capacity of 4 L, the height is 280 mm to 300 mm and its inside diameter is 145 mm to 155 mm. Its sides are flanged at the top. A fitted cover may be used to retard evaporation.² The shaft is positioned so that its axis is not more than 2 mm at any point from the vertical axis of the vessel and rotates smoothly and without significant wobble that could affect the results. A speed-regulating

device is used that allows the shaft rotation speed to be selected and maintained at the specified rate *given in the individual monograph, within $\pm 4\%$.

Shaft and basket components of the stirring element are fabricated of stainless steel, type 316, or other inert material, to the specifications shown in Figure 1. A basket having a gold coating of about 0.0001 inch (2.5 μ m) thick may be used. A dosage unit is placed in a dry basket at the beginning of each test. The distance between the inside bottom of the vessel and the bottom of the basket is maintained at 25 ± 2 mm during the test.

Apparatus 2 (Paddle Apparatus)

Use the assembly from Apparatus 1, except that a paddle formed from a blade and a shaft is used as the stirring element. The shaft is positioned so that its axis is not more than 2 mm from the vertical axis of the vessel at any point and rotates smoothly without significant wobble that could affect the results. The vertical center line of the blade passes through the axis of the shaft so that the bottom of the blade is flush with the bottom of the shaft. The paddle conforms to the specifications shown in Figure 2. The distance of 25 ± 2 mm between the bottom of the blade and the inside bottom of the vessel is maintained during the test. The metallic or suitably inert, rigid blade and shaft comprise a single entity. A suitable two-part detachable design may be used provided the assembly remains firmly engaged during the test. The paddle blade and shaft may be coated with a suitable coating so as to make them inert. The dosage unit is allowed to sink to the bottom of the vessel before rotation of




Fig. 1. Basket Stirring Element

¹ The materials should not sorb, react, or interfere with the specimen being tested.

² If a cover is used, it provides sufficient openings to allow ready insertion of the thermometer and withdrawal of specimens.

the blade is started. A small, loose piece of nonreactive material, such as not more than a few turns of wire helix, may be attached to dosage units that would otherwise float. An alternative sinker device is shown in *Figure 2a*. Other validated sinker devices may be used.

Apparatus 3 (Reciprocating Cylinder)

NOT ACCEPTED BY THE JAPANESE PHARMACOPOEIA

The assembly consists of a set of cylindrical, flat-bottomed glass vessels; a set of glass reciprocating cylinders; inert fittings (stainless steel type 316 or other suitable material), and screens that are made of suitable nonsorbing and nonreactive material and that are designed to fit the tops and bottoms of the reciprocating cylinders;

and a motor and drive assembly to reciprocate the cylinders vertically inside the vessels and, if desired, index the reciprocating cylinders horizontally to a different row of vessels. The vessels are partially immersed in a suitable water bath of any convenient size that permits holding the temperature at $37 \pm 0.5^\circ$ during the test. No part of the assembly, including the environment in which the assembly is placed, contributes significant motion, agitation, or vibration beyond that due to the smooth, vertically reciprocating cylinder. A device is used that allows the reciprocation rate to be selected and maintained at the specified dip rate *given in the individual monograph, within $\pm 5\%$. An apparatus that permits observation of the specimens and reciprocating cylinders is preferable. The vessels are provided with an evaporation cap that remains in place for the duration of the test. The components conform to the dimensions shown in *Figure 3* unless otherwise specified *in the individual monograph.




Fig. 2. Paddle Stirring Element




Fig. 2a. Alternative sinker. All dimensions are expressed in mm.




Fig. 3. Apparatus 3 (reciprocating cylinder)

Apparatus 4 (Flow-Through Cell)

The assembly consists of a reservoir and a pump for the *Dissolution Medium*; a flow-through cell; and a water bath that maintains the *Dissolution Medium* at $37 \pm 0.5^\circ$. Use the specified cell size as given in the individual monograph.

The pump forces the *Dissolution Medium* upwards through the flow-through cell. The pump has a delivery range between 240 and 960 mL per hour, with standard flow rates of 4, 8, and 16 mL per minute. It must deliver a constant flow ($\pm 5\%$ of the nominal flow rate); the flow profile is sinusoidal with a pulsation of 120 ± 10 pulses per minute.

The flow-through cell (see *Figures 4 and 5*), of transparent and inert material, is mounted vertically with a filter system (specified in the individual monograph) that prevents escape of undissolved particles from the top of the cell; standard cell diameters are 12 and 22.6 mm; the bottom cone is usually filled with small glass beads of about 1-mm diameter with one bead of about 5 mm positioned at the apex to protect the fluid entry tube; and a tablet holder (see *Figures 4 and 5*) is available for positioning of special dosage forms, for example, inlay tablets. The cell is immersed in a water bath, and the temperature is maintained at $37 \pm 0.5^\circ$.




Fig. 4. Large cell for tablets and capsules (top) Tablet holder for the large cell (bottom) (All measurements are expressed in mm unless noted otherwise.)




Fig. 5. Small cell for tablets and capsules (top) Tablet holder for the small cell (bottom) (All measurements are expressed in mm unless noted otherwise.)

The apparatus uses a clamp mechanism and two O-rings to assemble the cell. The pump is separated from the dissolution unit in order to shield the latter against any vibrations originating from the pump. The position of the pump should not be on a level higher than the reservoir flasks. Tube connections are as short as possible. Use suitably inert tubing, such as polytetrafluoroethylene, with about 1.6-mm inner diameter and chemically inert flanged-end connections.

APPARATUS SUITABILITY

The determination of suitability of a test assembly to perform dissolution testing must include conformance to the dimensions and tolerances of the apparatus as given above. In addition, critical test parameters that have to be monitored periodically during use include volume and temperature of the *Dissolution Medium*, rotation speed (*Apparatus 1* and *Apparatus 2*), dip rate (*Apparatus 3*), and flow rate of medium (*Apparatus 4*).

Determine the acceptable performance of the dissolution test assembly periodically. ♦ The suitability for the individual apparatus is demonstrated by the *Apparatus Suitability Test*.

Apparatus Suitability Test, Apparatus 1 and 2—Individually test 1 tablet of the USP Dissolution Calibrator, Disintegrating Type and 1 tablet of USP Dissolution Calibrator, Nondisintegrating Type, according to the operating conditions specified. The apparatus is suitable if the results obtained are within the acceptable range stated in the certificate for that calibrator in the apparatus tested.

Apparatus Suitability Test, Apparatus 3—Individually test 1 tablet of the USP Drug Release Tablets (Single Unit) according to the operating conditions specified. The apparatus is suitable if the results obtained are within the acceptable range stated in the certificate.

Apparatus Suitability Test, Apparatus 4—[To come.]

PROCEDURE

Apparatus 1 and Apparatus 2

IMMEDIATE-RELEASE DOSAGE FORMS

Place the stated volume of the *Dissolution Medium* ($\pm 1\%$) in the vessel of the specified apparatus ♦ given in the individual monograph. ♦, assemble the apparatus, equilibrate the *Dissolution Medium* to $37 \pm 0.5^\circ$, and remove the thermometer. Place 1 dosage unit in the apparatus, taking care to exclude air bubbles from the surface of the dosage unit, and immediately operate the apparatus at the specified rate ♦ given in the individual monograph. ♦. Within the time interval specified, or at each of the times stated, withdraw a specimen from a zone midway between the surface of the *Dissolution Medium* and the top of the rotating basket or blade, not less than 1 cm from the vessel wall. [NOTE—Where multiple sampling times are specified, replace the aliquots withdrawn for analysis with equal volumes of fresh *Dissolution Medium* at 37° or, where it can be shown that replacement of the medium is not necessary, correct for the volume change in the calculation. Keep the vessel covered for the duration of the test, and verify the temperature of the mixture under test at suitable times.] Perform the analysis ♦ as directed in the individual monograph. ♦, using a suitable assay method.³ Repeat the test with additional dosage form units.

If automated equipment is used for sampling or the apparatus is otherwise modified, verification that the modified apparatus will produce results equivalent to those obtained with the standard apparatus described in this general chapter is necessary.

Dissolution Medium—A suitable dissolution medium is used. Use the solvent specified ♦ in the individual monograph. ♦. The volume specified refers to measurements made between 20° and 25° . If the *Dissolution Medium* is a buffered solution, adjust the solution so that its pH is within 0.05 unit of the specified pH ♦ given in the individual monograph. ♦. [NOTE—Dissolved gases can cause bubbles to form, which may change the results of the test. If dissolved gases influence the dissolution results, dissolved gases should be removed prior to testing.⁴]

³ Test specimens are filtered immediately upon sampling unless filtration is demonstrated to be unnecessary. Use an inert filter that does not cause adsorption of the active ingredient or contain extractable substances that would interfere with the analysis.

⁴ One method of deaeration is as follows: Heat the medium, while stirring gently, to about 41° , immediately filter under vacuum using a filter having a porosity of $0.45 \mu\text{m}$ or less, with vigorous stirring, and continue stirring under vacuum for about 5 minutes. Other validated deaeration techniques for removal of dissolved gases may be used.

Time—Where a single time specification is given, the test may be concluded in a shorter period if the requirement for minimum amount dissolved is met. Specimens are to be withdrawn only at the stated times within a tolerance of $\pm 2\%$.

♦ **Procedure for a Pooled Sample for Immediate-Release Dosage Forms**—Use this procedure where *Procedure for a Pooled Sample* is specified in the individual monograph. Proceed as directed in *Procedure for Apparatus 1 and Apparatus 2* in *Immediate-Release Dosage Forms*. Combine equal volumes of the filtered solutions of the six or twelve individual specimens withdrawn, and use the pooled sample as the test specimen. Determine the average amount of the active ingredient dissolved in the pooled sample. ♦

EXTENDED-RELEASE DOSAGE FORMS

Proceed as directed for *Immediate-Release Dosage Forms*.

Dissolution Medium—Proceed as directed for *Immediate-Release Dosage Forms*.

Time—The test-time points, generally three, are expressed in hours.

DELAYED-RELEASE DOSAGE FORMS

NOT ACCEPTED BY THE JAPANESE PHARMACOPOEIA

Use *Method A* or *Method B* and the apparatus specified ♦ in the individual monograph. ♦. All test times stated are to be observed within a tolerance of $\pm 2\%$, unless otherwise specified.

Method A—

Procedure ♦ (unless otherwise directed in the individual monograph). ♦—

ACID STAGE—Place 750 mL of 0.1 N hydrochloric acid in the vessel, and assemble the apparatus. Allow the medium to equilibrate to a temperature of $37 \pm 0.5^\circ$. Place 1 dosage unit in the apparatus, cover the vessel, and operate the apparatus at the specified rate ♦ given in the monograph. ♦.

After 2 hours of operation in 0.1 N hydrochloric acid, withdraw an aliquot of the fluid, and proceed immediately as directed under *Buffer Stage*.

Perform an analysis of the aliquot using a suitable assay method. ♦ The procedure is specified in the individual monograph. ♦.

BUFFER STAGE—[NOTE—Complete the operations of adding the buffer and adjusting the pH within 5 minutes.]

With the apparatus operating at the rate specified ♦ in the monograph. ♦, add to the fluid in the vessel 250 mL of 0.20 M tribasic sodium phosphate that has been equilibrated to $37 \pm 0.5^\circ$. Adjust, if necessary, with 2 N hydrochloric acid or 2 N sodium hydroxide to a pH of 6.8 ± 0.05 . Continue to operate the apparatus for 45 minutes, or for the specified time ♦ given in the individual monograph. ♦. At the end of the time period, withdraw an aliquot of the fluid, and perform the analysis using a suitable assay method. ♦ The procedure is specified in the individual monograph. ♦. The test may be concluded in a shorter time period than that specified for the *Buffer Stage* if the requirement for the minimum amount dissolved is met at an earlier time. ♦.

Method B—

Procedure ♦ (unless otherwise directed in the individual monograph). ♦—

ACID STAGE—Place 1000 mL of 0.1 N hydrochloric acid in the vessel, and assemble the apparatus. Allow the medium to equilibrate to a temperature of $37 \pm 0.5^\circ$. Place 1 dosage unit in the apparatus, cover the vessel, and operate the apparatus at the rate specified ♦ in the monograph. ♦. After 2 hours of operation in 0.1 N hydrochloric acid, withdraw an aliquot of the fluid, and proceed immediately as directed under *Buffer Stage*.

Perform an analysis of the aliquot using a suitable assay method. ♦ The procedure is specified in the individual monograph. ♦.

BUFFER STAGE—[NOTE—For this stage of the procedure, use buffer that previously has been equilibrated to a temperature of $37 \pm 0.5^\circ$.] Drain the acid from the vessel, and add to the vessel 1000 mL of pH

6.8 phosphate buffer, prepared by mixing 0.1 N hydrochloric acid with 0.20 M tribasic sodium phosphate (3:1) and adjusting, if necessary, with 2 N hydrochloric acid or 2 N sodium hydroxide to a pH of 6.8 ± 0.05 . [NOTE—This may also be accomplished by removing from the apparatus the vessel containing the acid and replacing it with another vessel containing the buffer and transferring the dosage unit to the vessel containing the buffer.]

Continue to operate the apparatus for 45 minutes, or for the specified time *given in the individual monograph. At the end of the time period, withdraw an aliquot of the fluid, and perform the analysis using a suitable assay method. *The procedure is specified in the individual monograph. The test may be concluded in a shorter time period than that specified for the *Buffer Stage* if the requirement for minimum amount dissolved is met at an earlier time.

Apparatus 3 (Reciprocating Cylinder)

NOT ACCEPTED BY THE JAPANESE PHARMACOPOEIA

IMMEDIATE-RELEASE DOSAGE FORMS

Place the stated volume of the *Dissolution Medium* in each vessel of the apparatus, assemble the apparatus, equilibrate the *Dissolution Medium* to $37 \pm 0.5^\circ$, and remove the thermometer. Place 1 dosage-form unit in each of the six reciprocating cylinders, taking care to exclude air bubbles from the surface of each dosage unit, and immediately operate the apparatus as specified *in the individual monograph. During the upward and downward stroke, the reciprocating cylinder moves through a total distance of 9.9 to 10.1 cm. Within the time interval specified, or at each of the times stated, raise the reciprocating cylinders and withdraw a portion of the solution under test from a zone midway between the surface of the *Dissolution Medium* and the bottom of each vessel. Perform the analysis as directed *in the individual monograph. If necessary, repeat the test with additional dosage-form units.

Dissolution Medium—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

Time—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

EXTENDED-RELEASE DOSAGE FORMS

Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 3*.

Dissolution Medium—Proceed as directed for *Extended-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

Time—Proceed as directed for *Extended-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

DELAYED-RELEASE DOSAGE FORMS

Proceed as described for *Delayed-Release Dosage Forms, Method B* under *Apparatus 1* and *Apparatus 2* using one row of vessels for the acid stage media and the following row of vessels for the buffer stage media and using the volume of medium specified (usually 300 mL).

Time—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

Apparatus 4 (Flow-Through Cell)

IMMEDIATE-RELEASE DOSAGE FORMS

Place the glass beads into the cell specified *in the monograph. Place 1 dosage unit on top of the beads or, if specified *in the monograph, on a wire carrier. Assemble the filter head, and fix the parts together by means of a suitable clamping device. Introduce by the pump the *Dissolution Medium* warmed to $37 \pm 0.5^\circ$ through the bottom of the cell to obtain the flow rate specified *in the individual monograph, and measured with an accuracy of 5%. Collect the eluate by fractions at each of the times stated. Perform the analysis as directed *in the individual monograph. Repeat the test with additional dosage-form units.

Dissolution Medium—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

Time—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

EXTENDED-RELEASE DOSAGE FORMS

Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 4*.

Dissolution Medium—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 4*.

Time—Proceed as directed for *Immediate-Release Dosage Forms* under *Apparatus 4*.

DELAYED-RELEASE DOSAGE FORMS

Proceed as directed for *Delayed-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*, using the specified media.

Time—Proceed as directed for *Delayed-Release Dosage Forms* under *Apparatus 1* and *Apparatus 2*.

INTERPRETATION

Immediate-Release Dosage Forms

Unless otherwise specified *in the individual monograph, the requirements are met if the quantities of active ingredient dissolved from the dosage units tested conform to *Acceptance Table 1*. Continue testing through the three stages unless the results conform at either S_1 or S_2 . The quantity, Q , is the amount of dissolved active ingredient *specified in the individual monograph, expressed as a percentage of the labeled content of the dosage unit; the 5%, 15%, and 25% values in *Acceptance Table 1* are percentages of the labeled content so that these values and Q are in the same terms.

Acceptance Table 1

Stage	Number Tested	Acceptance Criteria
S_1	6	Each unit is not less than $Q + 5\%$.
S_2	6	Average of 12 units ($S_1 + S_2$) is equal to or greater than Q , and no unit is less than $Q - 15\%$.
S_3	12	Average of 24 units ($S_1 + S_2 + S_3$) is equal to or greater than Q , not more than 2 units are less than $Q - 15\%$, and no unit is less than $Q - 25\%$.

283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000

Acceptance Table for a Pooled Sample

Stage	Number Tested	Acceptance Criteria
S_1	6	Average amount dissolved is not less than $Q + 10\%$.
S_2	6	Average amount dissolved ($S_1 + S_2$) is equal to or greater than $Q + 5\%$.
S_3	12	Average amount dissolved ($S_1 + S_2 + S_3$) is equal to or greater than Q .

Extended-Release Dosage Forms

Unless otherwise specified *in the individual monograph, the requirements are met if the quantities of active ingredient dissolved from the dosage units tested conform to *Acceptance Table 2*. Continue testing through the three levels unless the results conform at either L_1 or L_2 . Limits on the amounts of active ingredient dissolved are expressed in terms of the percentage of labeled content. The limits embrace each value of Q , the amount dissolved at each specified fractional dosing interval. Where more than one range is specified *in the individual monograph, the acceptance criteria apply individually to each range.

Acceptance Table 2

Level	Number Tested	Criteria
L_1	6	No individual value lies outside each of the stated ranges and no individual value is less than the stated amount at the final test time.
L_2	6	The average value of the 12 units ($L_1 + L_2$) lies within each of the stated ranges and is not less than the stated amount at the final test time; none is more than 10% of labeled content outside each of the stated ranges; and none is more than 10% of labeled content below the stated amount at the final test time.
L_3	12	The average value of the 24 units ($L_1 + L_2 + L_3$) lies within each of the stated ranges, and is not less than the stated amount at the final test time; not more than 2 of the 24 units are more than 10% of labeled content outside each of the stated ranges; not more than 2 of the 24 units are more than 10% of labeled content below the stated amount at the final test time; and none of the units is more than 20% of labeled content outside each of the stated ranges or more than 20% of labeled content below the stated amount at the final test time.

Delayed-Release Dosage Forms

NOT ACCEPTED BY THE JAPANESE PHARMACOPOEIA.

Acid Stage—Unless otherwise specified *in the individual monograph, the requirements of this portion of the test are met if the quantities, based on the percentage of the labeled content, of active ingredient dissolved from the units tested conform to *Acceptance Table 3*. Continue testing through all levels unless the results of both acid and buffer stages conform at an earlier level.

Acceptance Table 3

Level	Number Tested	Criteria
A_1	6	No individual value exceeds 10% dissolved.
A_2	6	Average of the 12 units ($A_1 + A_2$) is not more than 10% dissolved, and no individual unit is greater than 25% dissolved.
A_3	12	Average of the 24 units ($A_1 + A_2 + A_3$) is not more than 10% dissolved, and no individual unit is greater than 25% dissolved.

Buffer Stage—Unless otherwise specified *in the individual monograph, the requirements are met if the quantities of active ingredient dissolved from the units tested conform to *Acceptance Table 4*. Continue testing through the three levels unless the results of both stages conform at an earlier level. The value of Q in *Acceptance Table 4* is 75% dissolved unless otherwise specified *in the individual monograph. The quantity, Q , *specified in the individual monograph, is the total amount of active ingredient dissolved in both the *Acid* and *Buffer Stages*, expressed as a percentage of the labeled content. The 5%, 15%, and 25% values in *Acceptance Table 4* are percentages of the labeled content so that these values and Q are in the same terms.

Acceptance Table 4

Level	Number Tested	Criteria
B_1	6	Each unit is not less than $Q + 5\%$.
B_2	6	Average of 12 units ($B_1 + B_2$) is equal to or greater than Q , and no unit is less than $Q - 15\%$.
B_3	12	Average of 24 units ($B_1 + B_2 + B_3$) is equal to or greater than Q , not more than 2 units are less than $Q - 15\%$, and no unit is less than $Q - 25\%$.